Royce & Associates LP Sells 81,317 Shares of Pediatrix Medical Group, Inc. $MD

Royce & Associates LP cut its stake in Pediatrix Medical Group, Inc. (NYSE:MD – Free Report) by 8.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 833,031 shares of the company’s stock after selling 81,317 shares during the period. Royce & Associates LP owned approximately 1.07% of Pediatrix Medical Group worth $21,434,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at $347,383,000. Dimensional Fund Advisors LP increased its position in shares of Pediatrix Medical Group by 8.1% in the first quarter. Dimensional Fund Advisors LP now owns 3,856,915 shares of the company’s stock worth $82,496,000 after purchasing an additional 287,696 shares during the period. Wasatch Advisors LP increased its position in shares of Pediatrix Medical Group by 21.9% in the second quarter. Wasatch Advisors LP now owns 2,498,884 shares of the company’s stock worth $63,297,000 after purchasing an additional 448,360 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Pediatrix Medical Group by 27.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,070,961 shares of the company’s stock worth $53,348,000 after purchasing an additional 452,051 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Pediatrix Medical Group by 12.9% in the first quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company’s stock valued at $32,776,000 after purchasing an additional 174,600 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on MD shares. UBS Group boosted their price target on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Wall Street Zen raised shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 13th. Jefferies Financial Group cut shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their target price for the company from $27.00 to $28.00 in a research report on Wednesday, August 19th. Weiss Ratings raised shares of Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, September 9th. Finally, Truist Financial upped their price target on shares of Pediatrix Medical Group from $28.00 to $31.00 and gave the stock a “hold” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Pediatrix Medical Group currently has an average rating of “Hold” and an average price target of $28.00.

View Our Latest Analysis on MD

Pediatrix Medical Group Trading Up 0.2%

Shares of MD stock opened at $31.35 on Monday. The stock’s fifty day moving average price is $27.88 and its two-hundred day moving average price is $24.34. The company has a market cap of $2.45 billion, a PE ratio of 17.04 and a beta of 0.62. Pediatrix Medical Group, Inc. has a fifty-two week low of $17.23 and a fifty-two week high of $33.74. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.28 and a current ratio of 1.28.

Pediatrix Medical Group (NYSE:MD – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.07. Pediatrix Medical Group had a return on equity of 20.12% and a net margin of 7.66%. The company had revenue of $501.37 million for the quarter, compared to analyst estimates of $498.18 million. During the same quarter last year, the company posted $0.67 EPS. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. Equities analysts predict that Pediatrix Medical Group, Inc. will post 2.22 EPS for the current fiscal year.

Pediatrix Medical Group Profile

(Free Report)

Pediatrix Medical Group provides physician services to hospitals and other healthcare facilities across the United States. Its clinicians care for women, newborns and children, working with healthcare partners to support patients in hospital and other clinical settings. The company’s services include neonatal care, maternal-fetal medicine and pediatric subspecialties. Its physicians and advanced practice providers deliver care such as treatment for high-risk pregnancies and specialized medical services for newborns and children.

Recommended Stories

Institutional Ownership by Quarter for Pediatrix Medical Group (NYSE:MD)

Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.